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ABSTRACT
Background: It is clinically important to detect and type human papillomavirus (HPV) in a sensitive 
and specific manner. Objectives: Development of a nested-polymerase chain reaction-restriction 
fragment length polymorphism (nested-PCR-RFLP) assay to detect and type HPV based on the 
analysis of L1 gene. Methods: Analysis of published DNA sequence of mucosal HPV types to se-
lect sequences of new primers. Design of an original nested-PCR assay using the new primers pair 
selected and classical MY09/11 primers. HPV detection and typing in cervical samples using the 
nested-PCR-RFLP assay. Results: The nested-PCR-RFLP assay detected and typed HPV in cervical 
samples. Of the total of 128 clinical samples submitted to simple PCR and nested-PCR for detection 
of HPV, 37 (28.9%) were positive for the virus by both methods and 25 samples were positive only by 
nested-PCR (67.5% increase in detection rate compared with single PCR). All HPV positive samples 
were effectively typed by RFLP assay. Conclusion: The method of nested-PCR proved to be an effec-
tive diagnostic tool for HPV detection and typing. 
Keywords: DNA probes, HPV; polymerase chain reaction; polymorphism, restriction; fragment 
length.
INTRODUCTION 
Cancer of the uterine cervix is one of the 
most important diseases among women 
worldwide, with approximately 500,000 new 
cases and 260,000 deaths per year.1 In Brazil, 
the National Cancer Institute (INCA) esti-
mates 18,430 new cases for this current year.2 
The infection with certain types of hu-
man papillomavirus (HPV) is recognized as 
a causal factor required for the development 
of cervical cancer.3 This virus belongs to the 
Papillomaviridae family and is further clas-
sified in 12 Papillomavirus genera infecting 
different animal species. Five of this genera 
(alfa, beta, gama, mu and nu) can infect hu-
mans and are classified according to the on-
cogenic potential in high (16, 18, 26, 30, 31, 
33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 
68, 69, 70, 73, 82) and low-risk types (6, 11, 
13, 32, 42, 43, 44, 54, 55, 61, 71, 72, 74, 81, 83, 
84, candHPV85).4
Molecular methods to detect HPV-DNA 
(mainly the oncogenic types) have already 
been developed and are currently used in 
clinical laboratories. The precise identifica-
tion of viral types is essential for clinical as-
sessment and monitoring of cervical diseases 
in women.5 The Hybrid Capture II (Qiagen) 
is a method widely used in many countries 
and is able to detect 18 HPV types. This 
method is based on a non-radioactive signal 
amplification method that uses two sets of 
RNA probes, one for low-risk (6, 11, 42, 43 
and 44) and another for high-risk types (16, 
18 , 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 
68). Despite being approved by the Food 
and Drug Administration (FDA), Hybrid 
Capture II has some important limitations, 
as it does not detect some HPV types, does 
not identify the specific type of HPV, is less 
sensitive than PCR and presents cross-reac-
tivity of the RNA probes (for low and high 
risk), reducing the clinical relevance of a 
positive result.6-10 
Alternatively, there are several PCR 
methods to detect HPV-DNA. The use of 
primers targeted to highly conserved con-
sensus sequences of the virus (mainly in the 
L1 region) allows simultaneous amplification 
of a large number of mucosal HPV types. The 
majority of the PCR methods use single PCR 
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amplification with two pairs of consensus primers: MY09/11 
or GP5+/6+.11,12 Primers pair MY09/11 has been largely 
used in clinical and epidemiological studies.13-16 One of the 
main advantages of this primers combination is the possibil-
ity of determining the HPV type using different procedures: 
restriction fragment length polymorphism (RFLP) assay, se-
quencing, and micro-array technology.10,17-20
Nested-PCR techniques have proven to be more sensi-
tive for the detection of HPV than PCR methods based on 
only one amplification reaction.21,22 A nested-PCR meth-
od using MY09/11 and GP5+/6+ primers has been used 
in large epidemiological studies for the sensitive detection 
of HPV in cervical samples.16 However, the nested-PCR 
techniques previously described require additional se-
quencing or hybridization procedures to accurately iden-
tify the HPV type.21,23 This study aimed to develop and 
validate a highly sensitive nested-PCR-RFLP methodol-
ogy for HPV detection and typing easily applied in limit-
ed-resource laboratories.
MATERIALS AND METHODS
The project “Evaluation of the use of HPV-DNA detection in 
screening for precancerous lesions and cervical neoplasia 
in an urban center in Southern Brazil” was approved by the 
Ethics Committee of Universidade de Cruz Alta under 
the protocol number 078.0.417-09.
Clinical samples 
The first group of samples included a panel of 44 clinical 
samples, positive and negative for HPV, previously analyzed 
in a molecular diagnostic laboratory. These samples were 
previously detected by the PCR-RFLP method and present-
ed the following HPV types: 6, 11, 16, 33, 53, 54, 56, 58, 61, 
62, 66, 70 (CP 141), 83 (MM7) and 84 (MM8). The second 
group included 84 samples obtained prospectively from 
women seeking routine care in a screening program for cer-
vical cancer in a public health service in southern Brazil. 
All the samples were collected by scraping the ecto and 
endocervix with individual brushes. Each brush was packed 
in a modified buffer solution (EDTA pH 8.0 0.01 M, SDS 
0.03 M) and conserved at -20°C until analysis.
HPV DNA sequences analysis 
Published DNA sequences of the main mucosal HPV types 
(6, 11, 13, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 
45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 68, 69, 70, 71, 72, 
73,74, 81, 82, 83, 84, 90, cand85, cand86, cand87, cand 89, 
cand91 - all of them classified in the Alpha-papillomavirus 
genus) were obtained from the GenBank database (http://
www.ncbi.nlm.nih.gov/Genbank/). These sequences were 
edited and aligned using EditSeq and MegAlign softwares 
from the DNAstar package (Lasergene Inc., USA), respec-
tively. DNA segments of the L1 gene were selected and 
compiled in a document file for primer design. The PCR 
primers pair was selected directly in the aligned sequenc-
es and the hybridization temperature was estimated using 
the PrimerSelect software also from the DNAstar package 
(Lasergene Inc., USA). 
DNA extraction
Total DNA of the clinical samples was purified by a 
standard silica/GuSCN-based procedure.24 Briefly, 100 µL 
of the liquid sample was added to 900 µL of lysis buff-
er (GuSCN 5 M, Tris-HCl 0.1 M, EDTA 0.5 M and Tri-
ton X-100) and then incubated at room temperature for 
10 min. After, 20 µL of silica suspension was added to 
each sample, mixed and centrifuged at 10,000 rpm for 
30 sec. The pellet was washed twice with 1.0 mL wash-
ing buffer (GuSCN 5 M and Tris-HCl 0.1 M), twice with 
75% ethanol and once with acetone. The silica suspension 
was dried at 56-60°C for 10 min. DNA was eluted with 50 
µL of TE buffer and the solution was separated from the 
silica particles centrifuging at 10,000 rpm for 3 min to use 
as template in PCR reaction.
HPV detection by PCR and nested-PCR assays
HPV-DNA was analyzed by PCR (with one amplification 
reaction) and nested-PCR assays. PCR was carried out in 
a total volume of 30 μL using 2 μL of template DNA, 1X 
PCR buffer (10 mM Tris-HCl pH 8.5, 50 mM KCl), 1.5 mM 
MgCl2, 0.0625 mM of each deoxynucleotide triphosphate 
(dATP, dTTP, dCTP, dGTP), 0.5 μM of each consensus 
primers MY09/MY11 and 1.6 U of Taq DNA polymerase 
(Cenbiot Enzimas, RS, Brazil). Thermal cycling was per-
formed in a PE Applied Biosystems 9700 Sequence Detector 
System with the following program: 4 min at 95°C, 35 cycles 
of 30 sec at 94°C, 30 sec at 56°C and 30 sec at 72°C, with final 
extension step at 72°C for 8 min.
Nested-PCR assay was performed in two consecutive 
amplification reactions. The first reaction was carried out 
in a total volume of 30 μL using 2 μL of template DNA, 
1X PCR buffer (10 mM Tris-HCl pH 8.5, 50 mM KCl), 
1.5 mM MgCl2, 0.0625 mM of each deoxynucleotide 
triphosphate (dATP, dTTP, dCTP, dGTP), 0.5 μM of each 
primer, 1 U of Taq DNA polymerase (Cenbiot Enzimas, 
RS, Brazil). Amplification was performed in a PE Applied 
Biosystems 9.700 with this program: 1 cycle at 95°C for 
3 min and 20 cycles at 95°C for 20 sec, 40°C for 40 sec and 
72°C for 1 min, followed by a final extension cycle at 72°C 
for 5 min. The second reaction was also carried out in a 
volume of 30 μL using 2 μL of amplified DNA, 0.25 μM of 
the primers (MY09/11) and the same reagents and con-
centrations described above. Thermal cycling was per-
formed in the same equipment with the following steps: 
1 cycle at 95°C for 3 min, 35 cycles at 95°C for 20 sec, 
55°C for 40 sec and 72°C for 1 min, and a final extension 
cycle at 72°C for 5 min.
HPV detection by a nested-PCR-RFLP assay
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Positive and negative samples were added as controls 
in all experiments for quality control. The amplified DNA 
products and molecular weight markers were then sub-
mitted to electrophoresis in 10% polyacrylamide gels at 
65 V for 1 hour. Each gel was stained with silver nitrate 
and positive/negative results were evaluated based on the 
presence of fragments of the expected size (~450 bp).
HPV typing by RFLP assay
All HPV positive samples were typed by RFLP analysis. 
Each restriction reaction was performed separately in a fi-
nal volume of 10 µL, using 2 µL of MY09/11 PCR product, 
1 µL of 10X recommended restriction buffer and 10 units 
of the following restriction endonucleases: PstI (New Eng-
land Biolabs, USA), HaeIII (New England Biolabs, USA), 
DdeI (New England Biolabs, USA), RsaI (Promega, USA) 
and HinfI (New England Biolabs, USA), according to the 
manufacturer’s instructions. Reactions were carried out 
at 37°C for 1 hour. Digested products were separated on 
10% polyacrylamide gels by electrophoresis together with 
a 50 bp DNA molecular weight marker (Promega, USA), 
and after stained with silver nitrate.
Confirmation of RFLP analysis by sequencing
PCR products were sequenced to confirm the RFLP results. 
Forward and reverse sequencing reactions were carried out 
using 15 to 30 ng of template DNA from PCR amplimers, 
3.2 pmol of the MY09 and MY11 primers (respectively) and 
4 µL of reagent BigDye Terminator v3.1 Cycle Sequencing 
(Applied Biosystems Inc., Norwalk, CT, USA) in a final vol-
ume of 20 µL. The sequencing rounds were performed in the 
thermocycler Veriti 96 (Applied Biosystems Inc., Norwalk, 
CT, USA) with the initial step of 95°C for 3 min followed by 
40 cycles of 95°C for 10 sec and 60°C for 240 sec. The sam-
ples were purified by ethanol/EDTA/sodium acetate proto-
col and the precipitated DNA products were diluted in 10 µL 
of formamide Hi-Di, denatured (95°C for 2 min) and inject-
ed in the automated DNA sequencing ABI 3130 XL Genetic 
Analyzer (Applied Biosystems Inc., Norwalk, CT, USA). The 
sequence data were collected using the Data Collection pro-
gram v1.0.1 with the parameters Dye Set “Z”. Quality analy-
sis was performed using the Sequencing Analysis v.5.3.1 
software by evaluating the main technical parameters as raw 
data, electropherogram and quality value of sequenced bases 
(Applied Biosystems Inc., Norwalk, CT, USA). The nucleo-
tide sequences of the same amplicon (primers sense and an-
tisense) were edited and assembled using SeqMan software 
(DNAStar, Madison, Wisconsin, USA). The nucleotide se-
quences of the samples were aligned using the MegAlign pro-
gram (DNAStar, Madison, Wisconsin, USA) and types were 
deduced from the phylogenies generated by the program 
itself. Further, data obtained were compared with sequenc-
es available in GenBank database (www.ncbi.nlm.nih.gov) 
using BLAST tool. 
RESULTS
Primers and nested-PCR-RFLP design
After alignment of the L1 HPV sequences obtained in 
GenBank, conserved sequence regions (upstream to 
MY09 primer and downstream to MY11 primer) were se-
lected and analyzed in PrimerSelect software (Lasergene 
Inc., USA). Considering a fitness combination for a prim-
ers pair and detection of all HPV types, the following 
sequences were selected: 5’-CAA WTR TTY AAT AAR 
CCW TAT TGG–3’ (primer SB01) and 5’-AAA AAY TTY 
CGW CCM ARR GG–3’ (primer SB02). PCR product is 
approximately 495 bp for the majority of HPV types. Us-
ing this primers pair, a novel detection and typing proce-
dure based on nested-PCR-RFLP assay was designed. The 
whole procedure consisted in a first amplification by PCR 
with low stringent condition (annealing temperature of 
40°C), a second amplification by PCR using MY09/11 
primers pairs (nested-PCR) and typing by restriction 
fragment length polymorphism (RFLP) assay.
This procedure was used to detect and type HPV in 
DNA samples extracted from two previously analyzed 
clinical samples with positive results for types 6 and 16. 
In both samples, the expected ~450 bp fragment of L1 
gene was successfully amplified by nested-PCR assay. 
Further, RFLP assay demonstrated the same pattern of 
the two types previously found (Figure 1). To confirm the 
specificity of the assay, the nested-PCR assay was also 
performed with DNA extracted from negative HPV cer-
vical samples. HPV specific fragments were not detected. 
Figure 1:	Restriction	enzyme	patterns	of	MY09/11	amplicon	
from	HPV	types	6	and	16.	Lanes	M,	50	bp	ladder	size	marker;	
lanes 1 to 5, HPV 6 digested with Rsa I, Dde I, Hinf I, Pst I and 
Hae III; lanes 1 to 5, HPV 6 digested with Rsa I, Dde I, Hinf I, 
Pst I and Hae III.
Coser, Boeira, Fonseca et al.
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Evaluation of the nested-PCR-RFLP assay with 
clinical samples 
The nested-PCR-RFLP assay was compared to MY09/11 
PCR assay using two groups of cervical samples. The first 
group had 44 previously analyzed cervical samples of a 
service laboratory, 24 HPV-DNA positive and 20 negative 
by MY09/11 PCR. A total of 36 samples were positive and 
8 negative using the nested-PCR assay. All the 24 positive 
samples by MY09/11 PCR were also positive by nested-PCR. 
In addition, 12 samples were exclusively positive for HPV 
by the nested-PCR assay (Table 1). Afterwards, 84 consecu-
tively collected cervical samples (second group), obtained 
from women who underwent routine examination for cervi-
cal cancer screening in a public health service in a city (Cruz 
Alta) of Rio Grande do Sul State (Southern Brazil), were an-
alyzed by both procedures (MY09/11 PCR and nested-PCR 
assays) in a blind fashion experiment. Again, all the positive 
samples by PCR (13) were also positive in the nested-PCR 
and other 13 samples were exclusively HPV positive using the 
nested-PCR assay (Table 1).
In the analysis by RFLP assay, 23 different HPV types 
were identified (12 high-risk and 11 low-risk). Importantly, 
two high-risk types (HPV 45 and HPV 73) and three low-risk 
types (HPV 44, HPV 71 and HPV 81) were detected only 
by nested-PCR-RFLP assay (Table 2). Mixed infections were 
identified in 14 samples and the HPV types (two in all sam-
ples) of each case were efficiently discriminated by the RFLP 
assay. DNA sequencing was consistent with the pattern ob-
tained by RFLP assay in all cases with only one HPV type in 
the sample. In the 14 mixed infection cases, DNA sequenc-
ing identified one of the types detected by RFLP assay.
DISCUSSION
The wide variation of HPV types and the occurrence of mul-
tiple infections by this virus require reliable methods for 
HPV detection and typing. These methodologies are essen-
tial for patient management by the clinician and even epi-
demiological studies. In the near future, HPV detection and 
typing will also be important in the screening and monitor-
ing of women that use specific vaccines or therapies.25 
HPV detection is based on the analysis of the viral DNA 
by different methods (hybrid-capture, PCR, hybridiza-
tion). In the PCR assays currently used, consensus primers 
(MY09/11, GP5+/6+, PGMY, SPF10) are targeted to the high-
ly conserved L1 region and detect different HPV types.12,26-28 
Previous studies have already demonstrated that the use 
of primers pair MY09/11 and GP5/GP6 in a nested-PCR 
assay increases the sensitivity of HPV detection compared 
with PCR assay.18,21,25,29,30 However, all of these studies used 
an additional sequencing and/or hybridization step of the 
amplification product for HPV typing.23
In this study, the development of a methodology based 
on nested-PCR technique, using an external primers pair 
in a first amplification and the “classical” primers pair 
MY09/11 in a second reaction, enabled the sensitive HPV 
detection in cervical samples. This was possible with the 
design of a new degenerated primers pair external to 
the region of the MY09/11 amplified product and the use of 
low stringent condition (annealing temperature of 40°C), 
Table 2. HPV types identified by RFLP in the positive samples after amplification with MY09/11 PCR and  
nested-PCR assays
 High-risk types (n)  Low-risk types (n)
MY09/11	PCR	 16	(6)b, 18 (1)b, 33 (6)b, 35 (1),  6 (2)b, 11 (4)b, 42 (2), 54 (5)b, 
and nested-PCR (n = 37) 52 (2)b, 53 (3)b, 56 (2)b, 61 (2)b, 62 (1), 83 (1)b, 84 (4)b 
 58 (2)b, 66 (4)b,	70	(1)
Only by nested-PCR (n = 25) 16 (2)b, 35 (1), 45a (4), 52 (1), 6 (1)b, 11 (1), 42 (1), 44a (1), 
 53 (1)b,	58	(2),	66	(1),	70	(3),	73a (2)b 54 (2), 62 (1), 71a (1)b, 81a (1)b, 84 (1)
a HPV types identified only by nested-PCR; b HPV types found in the 14 samples with mixed infection.
Table 1. Results of HPV-DNA detection using 
MY09/11 PCR in comparison to nested-PCR assays  
in two groups of cervical samples (pre-analyzed and 
prospectively collected)
  MY09/11 PCR
Nested-PCR Positive Negative Total 
 n = 37 n = 91 n = 128
First group
 Positive 24 12 36
	 Negative	 0	 8	 8
	 Total	 24	 20	 44
Second group
 Positive 13 13 26
	 Negative	 0	 58	 58
 Total 13 71 84
HPV detection by a nested-PCR-RFLP assay
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aiming the amplification of all cervical HPV types. In 
the analysis of pre-selected clinical samples (mostly pos-
itive) and cervical samples of a women group (mostly 
negative), an estimated 67.5% of increase in the rate of 
HPV detection was obtained as compared to MY09/11 
PCR. Husnjak et al.,31 comparing different techniques of 
PCR to detect HPV DNA in cervical samples, has report-
ed an increase of 38.8% detection rate using the method 
of nested-PCR (GP5/GP6) compared to single PCR am-
plification. Furthermore, in our study, all the 37 positive 
samples by PCR with MY09/11 primers were also detected 
by the nested-PCR assay (there were no cases of HPV de-
tected by MY09/11 PCR and not detected by nested-PCR). 
Considering PCR with MY09/11 primers as the “gold 
standard”, the clinical sensitivity and specificity were 100% 
and 72%, respectively. But it is important to consider that 
PCR with MY09/11 primers has clearly a lower analytical 
sensitivity than the nested-PCR assay developed in our study 
and this is the probable reason for the low clinical specific-
ity of the assay. Previous works have already demonstrated a 
higher analytical sensitivity for other nested-PCR assays.25,30 
We further classified the samples into two groups (positive 
by both procedures versus positive only by nested-PCR) 
and observed different patterns of HPV types and frequency 
by RFLP and sequencing. Some types were detected only by 
nested-PCR, as for example the high-risk types 45 and 73 
and the low-risk types 44, 71 and 81 (Table 2). This rein-
forces that the samples positive only in the nested-PCR assay 
are probably not false-positive results, but due to the higher 
analytical sensitivity of this assay. Other studies have also 
used nested-PCR assays to maximize the detection of HPV 
in different populations.16,21,23,32
Besides the increase in the analytical sensitivity, an-
other advantage of this new methodology is the possibil-
ity to perform HPV typing by RFLP assay, an easier and 
cheaper methodology than sequencing. In our study, the 
nested-PCR-RFLP assay detected precisely low (11, 42, 44, 
54, 62, 70, 81, 84) and high-risk types (16, 18, 33, 35, 45, 52, 
53, 58, 73). All these results were confirmed by DNA sequenc-
ing. These findings are similar to those reported by Aedo et 
al.,18 which identified 13 different types in samples tested 
with nested-PCR-RFLP in Chile. Similarly, Camara et al.33 
using the methodology of PCR-RFLP identified 13 viral 
types in women of the Distrito Federal, Brazil.
The methodology presented in this paper combines 
an easy and fast DNA extraction procedure, a sensitive 
nested-PCR amplification technique and a RFLP procedure 
that identify the main cervical HPV types. The procedure is 
suitable for the detection and characterization of HPV-DNA 
in public health programs to screen this virus in the popu-
lation and would be also a useful tool for HPV epidemio-
logical control, determining the circulating types in different 
geographical regions. Furthermore, it could be easily per-
formed in limited-resource laboratories, not requiring ad-
ditional sequencing or hybridization procedures (and all the 
equipment necessary) to accurately identify the HPV type.
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